Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man
- 1 February 1987
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 32 (2) , 139-144
- https://doi.org/10.1007/bf01297101
Abstract
The effect of 50-, 100-, 200-, and 400-mg oral doses of acarbose, a competitive inhibitor of intestinal α-glucosidases, on the postprandial release of gut and pancreatic hormones after a 2.2 MJ carbohydrate-rich mixed test meal was determined in five normal subjects according to a double-blind, Latin-square protocol. All the doses of acarbose tested slowed the postprandial plasma glucose rise, without evidence of dose dependency, while maximal inhibition of integrated insulin and gastric inhibitory polypeptide responses to 31 ±8% and 28±7% of control values, respectively, was obtained at the 400-mg dose. The enteroglucagon response was increased to a maximum of 905±262% of control at the 200-mg dose, and total motilin responses were slightly but not significantly elevated. After one week of regular acarbose administration at 100 mg three times daily, the effects of the 100-mg dose on insulin and enteroglucagon responses were slightly enhanced, and there was no evidence of intestinal adaptation in the form of diminished postprandial endocrine responses. The observed effects are attributed to impairment of carbohydrate digestion in the upper small intestine and suggest that the optimal ratio of desired to unwanted effects is obtained at low doses of acarbose.Keywords
This publication has 35 references indexed in Scilit:
- LOW DOSE ACARBOSE WITHOUT SYMPTOMS OF MALABSORPTION IN THE DUMPING SYNDROMEThe Lancet, 1982
- Response of Serum Levels of Gastric Inhibitory Polypeptide and Insulin to Sucrose Ingestion During Long-term Application of AcarboseScandinavian Journal of Gastroenterology, 1981
- A RADIOIMMUNOASSAY OF GASTRIC INHIBITORY POLYPEPTIDE IN HUMAN PLASMAJournal of Endocrinology, 1980
- COMBINED USE OF GUAR AND ACARBOSE IN REDUCTION OF POSTPRANDIAL GLYCÆMIAThe Lancet, 1979
- Effect of the?? glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabeticsDiabetologia, 1979
- A GLYCOSIDE-HYDROLASE INHIBITOR IN TREATMENT OF DUMPING SYNDROMEThe Lancet, 1979
- The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in manZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in manZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- Inhibition of human intestinalα-glucosidehydrolases by a new complex oligosaccharideZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- α-GLUCOSIDE HYDROLASE INHIBITION IN DIABETESThe Lancet, 1978